TY - JOUR ID - 90194 TI - Novel Approach using shRNA of IQGAP1 for Colon Cancer Therapy: HCT116 as a Surrogate Model Colorectal Carcinoma JO - Asian Pacific Journal of Cancer Prevention JA - APJCP LA - en SN - 1513-7368 AU - Zoheir, Khairy M M A AU - Mahmoud, khaled AU - Harisa, Gamal I. AU - Ashour, Abdelkader AU - Abdel-Hamied, Hala E AU - Amara, Amro A AU - Mahrous, Karima F AU - Abd-Rabou, Ahmed A AD - Cell Biology Department, Biotechnology Research Institute, National Research Centre, 33 Bohouth St., 12622, Dokki, Cairo, Egypt. AD - Pharmacognosy Department, National Research Centre, El-Behooth St., 12622 Dokki, Cairo, Egypt. AD - Pharmaceutical Industries, Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. AD - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Sinai University, 41636 Kantara Branch, Egypt. AD - Department of Pharmacology and Toxicology, College of Pharmacy, Al-Azhar University, Cairo, Egypt. AD - Protein Research Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications, Alexandria, Egypt. AD - Hormones Department, Medicine and Clinical Studies Research Institute, National Research Centre, Cairo, 12622 Egypt. Y1 - 2022 PY - 2022 VL - 23 IS - 7 SP - 2387 EP - 2395 KW - Colon cancer KW - shRNA KW - IQGAP1 KW - Cell migration KW - Apoptosis DO - 10.31557/APJCP.2022.23.7.2387 N2 - Background: Colorectal carcinoma (CRC) represents life-threatening problems worldwide. IQ motif containing GTPase activating protein 1 (IQGAP1) is acting as oncogenesis regulators. RNAi is proposed as promising cancer therapeutics. Objective: The objective of this work to explore the consequences of the IQGAP1 silence as a goal for treating CRC using the HCT166 cells as a model for human colon cancer. Methods: RNAi technology was used to design a short specific sequence of RNA (shRNA) to silence the IQGAP1 oncogene. The impact of IQGAP1 silencing on IQGAPs, Ras, IL-8, and TRAIL was investigated. Furthermore, the effect of IQGAP1 silencing on cell viability, proliferation, apoptosis, and invasive capacity was investigated. Results: The present results revealed that IQGAP1 shRNA-treated HCT166 cells showed no invasive capacity compared to the control cells. The silencing of IQGAP1 induced remarkable downregulation of IQGAP1, RAS (H&K), IL-8, CXCR1, CXCR2, NF-kB, BCL-2, and apoptosis of HCT166 cells. On the contrary, IQGAP2, IQGAP3, DR4, DR5, CASP-3, and BAX genes were significantly up-regulated. Conclusion: The IQGAP1 regulates the expression of IQGAPs, Ras, IL-8 receptors, and the apoptotic network. Therefore, the silence of IQGAP1 is a promising strategy for colon cancer therapy. UR - https://journal.waocp.org/article_90194.html L1 - https://journal.waocp.org/article_90194_291491ffb3af28f96670bdee0cf96fdf.pdf ER -